A further 2,900 additional cases have been dismissed.
The Anglo-Swedish drugmaker said the payouts would not affect its recently raised forecast for 2010 "core" earnings per share of $6.35 to $6.65, since any provision would be disregarded in calculating this underlying measure of profit.
The best-selling medicine, which had sales of worldwide sales of $4.9bn in 2009, has been linked to an increased risk of diabetes and has been subject to long-running legal claims.
News of the settlement agreements is not unexpected. Sources familiar with the situation had already said last week that AstraZeneca had agreed to pay around $55m to settle some 5,500 US claims.